| Revenue growth | FY26 +2%; Q4 +2%. Underlying growth ~5-6%. |
|---|---|
| Margins | EBITDA margin expanded to 34% (up 290bps YoY). |
| Demand visibility | Strong for promoted brands like Augmentin and Calpol. |
| Management confidence | High; confident in bridging growth gap via new launches. |
Growth
FY26 revenues up 2%, EBITDA grew 11%, and PAT (excl. exceptionals) crossed ₹1,000cr milestone (+10%).
Outlook
Targeting 10% top-line contribution from new innovation portfolio; multiple oncology and vaccine launches planned for FY27.
Risks
CMO fire disruption impacted GenMed sales by ₹100cr+; NLEM exposure covers 40% of business.
Earnings Call filed with BSE, NSE: GLAXO. Summary written with AI assistance from the document.
GlaxoSmithKline Pharmaceuticals Ltd: key numbers
- Share price
- ₹2,755.00
- Market cap
- ₹46,671 Cr
- Revenue (annual)
- ₹3,822 Cr
- Net profit (annual)
- ₹1,036 Cr
- P/E (TTM)
- 43.7×Sector 47.4×
- Promoter holding
- 75.00%+0.00% QoQ
- FII holding
- 4.79%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from GlaxoSmithKline Pharmaceuticals Ltd
All →GlaxoSmithKline Pharmaceuticals Annual General Meeting
GSK Pharma's postal ballot approved Ms. Natland as NED and Mr. Akshikar's MD re-appointment. Both resolutions cleared with over 99% shareholder support.
GlaxoSmithKline Pharmaceuticals Annual General Meeting
GlaxoSmithKline Pharmaceuticals issued a corrigendum for its August 3, 2026, postal ballot notice, correcting a typographical error in a reported salary figure.
GlaxoSmithKline Pharmaceuticals Price Movement Clarification
GlaxoSmithKline Pharmaceuticals clarified that recent trading volume increases are purely market-driven. The company confirmed all material disclosures have been made according to SEBI regulations.
GlaxoSmithKline Pharmaceuticals Business Update
GlaxoSmithKline Pharmaceuticals received an income tax refund intimation of Rs 4.99 Crore for the assessment year 2025-2026.
- Value
- ₹4.99 Cr
GlaxoSmithKline Pharmaceuticals Annual General Meeting
GlaxoSmithKline Pharmaceuticals has issued a Postal Ballot notice for shareholder approval. The resolutions involve appointing Karine J F Natland and re-appointing Bhushan Akshikar as Managing Director.
GlaxoSmithKline Pharmaceuticals Legal & Regulatory
GlaxoSmithKline Pharmaceuticals received a ₹52.00 Crore tax refund plus ₹42.09 Crore interest income following a favorable CIT-Appeal order for assessment year 1984-85.
- Value
- ₹94.09 Cr